News & Updates
Filter by Specialty:
Show Multimedia Only
Two-drug combo rises to the challenge as 1L Tx for mTNBC
02 Jul 2025
byAudrey Abella
In the primary analysis of the ASCENT-04/KEYNOTE-D19 study, a combination regimen comprising sacituzumab govitecan (SG) and pembrolizumab delivers significant progression-free survival (PFS) benefit in women with previously untreated PD-L1+ advanced triple-negative breast cancer (TNBC).
Two-drug combo rises to the challenge as 1L Tx for mTNBC
02 Jul 2025
Add-on olanzapine prevents RT-induced nausea, vomiting
01 Jul 2025
byStephen Padilla
In patients undergoing abdominal-pelvic radiation therapy (RT), treatment with olanzapine along with an antiemetic medication leads to a substantial decrease in RT-induced nausea and vomiting (RINV), with no serious adverse effects, reports a study presented at ASCO 2025.
